Drug intelligence / Profile preview

lutetium (177Lu) 6A10 Fab fragment

Development stage: Unknown
Lead developer: ITM Isotope Technologies Munich
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intratumoral

Overview

Lutetium-177 labelled 6A10 antibody Fab fragment is a radioimmunotherapeutic agent consisting of a Fab fragment of the monoclonal antibody 6A10, which targets carbonic anhydrase XII (CA XII), conjugated to the beta-emitting radioisotope lutetium-177. Developed by the University Hospital Münster (Universitaetsklinikum Muenster), it is being investigated for the treatment of high-grade gliomas, including glioblastoma. The therapy is administered directly into the tumor resection cavity (intracavitary) following standard radiochemotherapy and adjuvant chemotherapy. By targeting CA XII, an enzyme overexpressed in glioblastoma cells and associated with hypoxia and poor prognosis, the agent delivers localized ionizing radiation to residual tumor cells while minimizing systemic exposure.

Other names: lutetium-177 labelled 6A10 antibody Fab fragmentlutetium177 labelled 6A10 antibody Fab fragmentlutetium 177 labelled 6A10 antibody Fab fragment177Lu-6A10 Fab[177Lu]Lu-6A10-Fab177Lu-6A10 Fab fragment

Targets

CA12 (Carbonic anhydrase XII)

Beyond the preview

Go deeper on lutetium (177Lu) 6A10 Fab fragment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium (177Lu) 6A10 Fab fragment.

Explore the full profile